Sofinnova invests in Abivax to delay cash crunch by Nick Paul Taylor Friday, July 12, 2019 The investment extends Abivax’s cash runway out to the middle of 2020, buying the biotech time to find a partner for ABX464.
Abivax posts ulcerative colitis data, commits to phase 2b by Nick Paul Taylor Tuesday, September 4, 2018 The trial linked ABX464 to improvements in mucosal healing and performance on a symptom scale, leading Abivax to commit to a phase 2b.
Abivax, buoyed by HIV milestone, leads surge in value of biotech stocks in Paris by Nick Paul Taylor Thursday, September 15, 2016 Abivax's share price has surged more than 160% in a little more than one trading session on the back of news regarding its HIV collaboration.
